Literature DB >> 23469895

BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic infiltration is present.

Vincenzo Marotta1, Anna Guerra, Maria C Zatelli, Ettore Degli Uberti, Vincenza Di Stasi, Antongiulio Faggiano, Annamaria Colao, Mario Vitale.   

Abstract

BACKGROUND: Concomitant papillary thyroid cancer (PTC) and Hashimoto's thyroiditis (HT) is a frequent occurrence. Whether these two conditions are linked and whether PTC with concurrent HT has distinct clinicopathological characteristics are still debated issues. Lymphocytic infiltration is abundant in HT and might be relevant in the pathogenesis and progression of PTC. BRAF(V600E) mutation is associated with a more advanced PTC at diagnosis; however, its role in the clinicopathological characteristics of PTC with concurrent HT is unknown. DESIGN AND PATIENTS: We enrolled 146 patients with histological diagnosis of PTC. Microscopic assessment of histology samples was performed to identify the presence of lymphocytic infiltration. Detection of BRAF(V600E) was performed on cytology samples by both direct sequencing and pyrosequencing, and results were correlated with clinical parameters.
RESULTS: Concurrent HT lymphocytic infiltration was associated with the female gender, smaller tumour size, a less frequent extracapsular extension and a lower grade of TNM staging. BRAF(V600E) was more frequent in PTC with concomitant lymphocytic infiltration. In PTC harbouring BRAF(V600E) , concurrent lymphocytic infiltration was still associated with the female gender, a less frequent extracapsular extension and a lower TNM staging.
CONCLUSIONS: These results suggest that lymphocytic infiltration of HT is a protective factor against PTC progression, and it is independent of BRAF mutational status.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23469895     DOI: 10.1111/cen.12194

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  24 in total

Review 1.  The micropapillary/hobnail variant of papillary thyroid carcinoma: A review of series described in the literature compared to a series from one southern Italy pathology institution.

Authors:  Antonio Ieni; Valeria Barresi; Roberta Cardia; Luana Licata; Flavia Di Bari; Salvatore Benvenga; Giovanni Tuccari
Journal:  Rev Endocr Metab Disord       Date:  2016-12       Impact factor: 6.514

2.  Radioiodide induces apoptosis in human thyroid tissue in culture.

Authors:  Eleonora Russo; Anna Guerra; Vincenzo Marotta; Antongiulio Faggiano; Annamaria Colao; Silvana Del Vecchio; Massimo Tonacchera; Mario Vitale
Journal:  Endocrine       Date:  2013-03-31       Impact factor: 3.633

3.  Association between Hashimoto thyroiditis and clinical outcomes of papillary thyroid carcinoma: A meta-analysis.

Authors:  Qizhi Tang; Weiyu Pan; Liangyue Peng
Journal:  PLoS One       Date:  2022-06-16       Impact factor: 3.752

Review 4.  The increasing prevalence of chronic lymphocytic thyroiditis in papillary microcarcinoma.

Authors:  Roberto Vita; Antonio Ieni; Giovanni Tuccari; Salvatore Benvenga
Journal:  Rev Endocr Metab Disord       Date:  2018-12       Impact factor: 6.514

5.  The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma.

Authors:  Pierre Vanden Borre; David G McFadden; Viswanath Gunda; Peter M Sadow; Shohreh Varmeh; Maria Bernasconi; Tyler Jacks; Sareh Parangi
Journal:  Thyroid       Date:  2014-01-24       Impact factor: 6.568

6.  Does papillary thyroid carcinoma have a better prognosis with or without Hashimoto thyroiditis?

Authors:  Hee Yong Kwak; Byung Joo Chae; Yong Hwa Eom; Young Ran Hong; Jae Beom Seo; So Hee Lee; Byung Joo Song; Sang Seol Jung; Ja Seong Bae
Journal:  Int J Clin Oncol       Date:  2014-10-15       Impact factor: 3.402

7.  BRAF(V600E) assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto's thyroiditis is a reliable assay.

Authors:  Anna Guerra; Vincenza Di Stasi; Pio Zeppa; Antongiulio Faggiano; Vincenzo Marotta; Mario Vitale
Journal:  Endocrine       Date:  2013-06-18       Impact factor: 3.633

8.  The Warthin-Like Variant of Papillary Thyroid Carcinoma: A Comparison with Classic Type in the Patients with Coexisting Hashimoto's Thyroiditis.

Authors:  Min-Kyung Yeo; Ja Seong Bae; Sohee Lee; Min-Hee Kim; Dong-Jun Lim; Youn Soo Lee; Chan Kwon Jung
Journal:  Int J Endocrinol       Date:  2015-04-23       Impact factor: 3.257

Review 9.  Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review.

Authors:  Anna Guerra; Vincenzo Di Crescenzo; Alfredo Garzi; Mariapia Cinelli; Chiara Carlomagno; Massimo Tonacchera; Pio Zeppa; Mario Vitale
Journal:  BMC Surg       Date:  2013-10-08       Impact factor: 2.102

10.  Co-existence of BRAFV600E and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis.

Authors:  Haoyu Ren; Yifan Shen; Daixing Hu; Wei He; Jing Zhou; Yijia Cao; Yu Mao; Yi Dou; Wei Xiong; Qi Xiao; Yuhong Zhang; Xinliang Su
Journal:  Cancer Manag Res       Date:  2018-05-03       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.